Skip to content
‹ Back to IndustriesSciences

NASA Joins the International Effort to Learn More About Norway’s Auroral Cusp

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share

Key takeaways

01

A solar wind of ionized particles from the sun is constantly blowing through the solar system.

02

Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole.

03

Mars has no atmosphere because, after it lost its protective magnetic…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic field, the solar winds literally blew the atmosphere away. The earth’s active magnetic field is what keeps the same thing from happening here, and life disappearing from earth.

Near the poles, however, where the magnetic field bends in toward the earth, the solar wind can come into contact with the atmosphere, heating up the atmosphere and causing the auroras as the ionized particles bombard air molecules. According to Eureka Alert!, “North of Norway over the Norwegian and Greenland Seas, the magnetic bubble surrounding the Earth dips inward, allowing space particles to funnel in toward the planet.” This cusp, where energy from the solar wind “heats the atmosphere by hundreds of degrees,” is actually visible to the naked eye in November and December.

This is why “eight missions with 11 rockets will launch from two sites in Norway—Andøya Space Center and Svalbard Rocket Range” around this time in 2018 and 2019. “The first mission—a NASA mission called the Auroral Zone Upwelling Rocket Experiment, or AZURE—launches in March 2018.” NASA will also launch “the Visualizing Ion Outflow via Neutral Atom Sensing-2 experiment or VISIONS-2” in December 2018. There will also be the “Norwegian Investigation of Cusp Irregularities-5 or ICI-5 mission in December 2019.”

The Eureka Alert website further explains, “In addition to AZURE, VISIONS-2 and ICI-5, other NASA Grand Challenge missions are the Twin Rockets to Investigate Cusp Electrodynamics or TRICE-2 (led by the University of Iowa, launching December 2018), The Cusp Alfven and Plasma Electrodynamics Rocket or CAPER-2 (led by Dartmouth University, launching January 2019), and the Cusp-Region Experiment or C-REX 2 (led by the University of Alaska, launching November 2019), which also includes three Canadian instruments from the University of Calgary (also flying on VISIONS-2).” Furthermore, “The Japan Aerospace Exploration Agency (JAXA) will fly the SS-520-3 in January 2019, which investigates the ion outflow mechanism in the cusp.”

The next year will be exciting for both atmospheric and space science at the international level. By learning more about this unique feature in our atmosphere created by the earth’s magnetic field, we will learn more about the solar wind, how the solar wind interacts with the atmosphere, and how our magnetic field protects life on earth. So, stay tuned to science news over the next several years as new data surfaces and more knowledge about the cusp is created.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM platform

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show whether a worldwide migration is moving.

Nov 7, 2026

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512